176 related articles for article (PubMed ID: 29535057)
21. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Buggisch P; Vermehren J; Mauss S; Günther R; Schott E; Pathil A; Boeker K; Zimmermann T; Teuber G; Vornkahl HP; Simon KG; Niederau C; Wedemeyer H; Zeuzem S
J Hepatol; 2018 Apr; 68(4):663-671. PubMed ID: 29133244
[TBL] [Abstract][Full Text] [Related]
22. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
23. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
Babatin MA; AlGhamdi AS; Assiri AM; AlBiladi H; AlOthmani HS; Mogharbel MH; Mahallawi W; Asselah T; Sanai FM
Saudi J Gastroenterol; 2019; 25(1):55-60. PubMed ID: 30117490
[TBL] [Abstract][Full Text] [Related]
24. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Isakov V; Gankina N; Morozov V; Kersey K; Lu S; Osinusi A; Svarovskaia E; Brainard DM; Salupere R; Orlova-Morozova E; Zhdanov K
Clin Drug Investig; 2018 Mar; 38(3):239-247. PubMed ID: 29177645
[TBL] [Abstract][Full Text] [Related]
25. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
[TBL] [Abstract][Full Text] [Related]
26. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
Lawitz E; Poordad F; Hyland RH; Wang J; Liu L; Dvory-Sobol H; Brainard DM; McHutchison JG; Gutierrez JA
Antivir Ther; 2016; 21(8):679-687. PubMed ID: 27348483
[TBL] [Abstract][Full Text] [Related]
27. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data.
Andres J; Lott S; Qureshi K
J Manag Care Spec Pharm; 2018 Jan; 24(1):23-28. PubMed ID: 29290174
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years.
Behairy BE; El-Araby HA; El-Guindi MA; Basiouny HM; Fouad OA; Ayoub BA; Marei AM; Sira MM
J Pediatr; 2020 Apr; 219():106-110. PubMed ID: 32008767
[TBL] [Abstract][Full Text] [Related]
29. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lawitz E; Poordad FF; Pang PS; Hyland RH; Ding X; Mo H; Symonds WT; McHutchison JG; Membreno FE
Lancet; 2014 Feb; 383(9916):515-23. PubMed ID: 24209977
[TBL] [Abstract][Full Text] [Related]
30. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Nehra V; Tan EM; Rizza SA; Temesgen Z
Drugs Today (Barc); 2016 Feb; 52(2):111-7. PubMed ID: 27092340
[TBL] [Abstract][Full Text] [Related]
31. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
Ojha RP; MacDonald BR; Chu TC; Fasanmi EO; Moore JD; Stewart RA
Antivir Ther; 2018; 23(7):585-592. PubMed ID: 29969099
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
[TBL] [Abstract][Full Text] [Related]
34. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
[TBL] [Abstract][Full Text] [Related]
35. Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
Makhlouf NA; Abdelmalek MO; Ibrahim ME; Abu-Faddan NH; Kheila AE; Mahmoud AA
J Pediatric Infect Dis Soc; 2021 Feb; 10(1):7-13. PubMed ID: 32060510
[TBL] [Abstract][Full Text] [Related]
36. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Afdhal N; Reddy KR; Nelson DR; Lawitz E; Gordon SC; Schiff E; Nahass R; Ghalib R; Gitlin N; Herring R; Lalezari J; Younes ZH; Pockros PJ; Di Bisceglie AM; Arora S; Subramanian GM; Zhu Y; Dvory-Sobol H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Sulkowski M; Kwo P;
N Engl J Med; 2014 Apr; 370(16):1483-93. PubMed ID: 24725238
[TBL] [Abstract][Full Text] [Related]
37. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
38. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
39. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Quintero J; Juampérez J; Julio E; Cabello V; Mercadal-Hally M; Soler-Palacín P; Segarra Ó; Rodrigo C
An Pediatr (Engl Ed); 2019 Mar; 90(3):141-147. PubMed ID: 30126773
[TBL] [Abstract][Full Text] [Related]
40. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Singh T; Guirguis J; Anthony S; Rivas J; Hanouneh IA; Alkhouri N
Liver Int; 2016 Jun; 36(6):802-6. PubMed ID: 26824848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
